DDrare: Database of Drug Development for Rare Diseases

Searched query = "Lymphangioleiomyomatosis", "LAM"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 68Ga-NEB; Afinitor; Afinitor 5mg Tablets; Albuterol; Albuterol inhaler; Albuterol nebulizer; Bevacizumab; Celecoxib; Cetuximab; Doxycycline; Doxycycline 100 mg Capsules; EVEROLIMUS; Everolimus; Everolimus (RAD001); Everolimus Oral Product; Glutamine; Hydroxychloroquine; Imatinib; Imatinib Mesylate 400Mg Capsule; Letrozole; Nintedanib; Octreotide; Ofev; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; PFT; Procedure: PFT; RAD001; RAD001 5mg; Rapamycin; Rapamycin, sirolimus; Resveratrol; Saracatinib; Simvastatin; Sirolimus; Sirolimus Oral Product; Sirolimus and Hydroxychloroquine 200 mg; Sirolimus and Hydroxychloroquine 400 mg; Srolimus; Temsirolimus; Valproic Acid; Valproic acid

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03062943 (ClinicalTrials.gov)	October 2016	7/10/2016	A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)	A Pilot Study of Nintedanib for LymphAngioleioMyomatosis (LAM)	Lymphangioleiomyomatosis	Drug: Nintedanib	IRCCS Multimedica	NULL	Recruiting	18 Years	N/A	Female	30	Phase 2	Italy
2	EUCTR2015-004919-20-IT (EUCTR)	09/03/2016	11/08/2016	A pilot study of nintedanib for lymphangioleiomyomatosis (LAM)	A pilot study of nintedanib for lymphangioleiomyomatosis (LAM) - A pilot study of nintedanib for lymphangioleiomyomatosis (LAM)	Female subjects affected by Llymphangioleiomyomatosis (LAM) MedDRA version: 19.0;Level: PT;Classification code 10049459;Term: Lymphangioleiomyomatosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Trade Name: Ofev	MULTIMEDICA S.P.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: no	30	Phase 3	Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03062943
(ClinicalTrials.gov)

October 2016

7/10/2016

A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)

A Pilot Study of Nintedanib for LymphAngioleioMyomatosis (LAM)

Lymphangioleiomyomatosis

Drug: Nintedanib

IRCCS Multimedica

NULL

Recruiting

18 Years

N/A

Female

Phase 2

Italy

EUCTR2015-004919-20-IT
(EUCTR)

09/03/2016

11/08/2016

A pilot study of nintedanib for lymphangioleiomyomatosis (LAM)

A pilot study of nintedanib for lymphangioleiomyomatosis (LAM) - A pilot study of nintedanib for lymphangioleiomyomatosis (LAM)

Female subjects affected by Llymphangioleiomyomatosis (LAM)
MedDRA version: 19.0;Level: PT;Classification code 10049459;Term: Lymphangioleiomyomatosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]

Trade Name: Ofev

MULTIMEDICA S.P.A.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: no

Phase 3

Italy